https://www.selleckchem.com/products/ly333531.html
The approved maintenance regimens for ustekinumab in Crohn's disease (CD) are 90mg every 8 or 12 weeks. Some patients will partially respond to ustekinumab or will experience a secondary loss of response. It remains poorly known if these patients may benefit from shortening the interval between injections. All patients with active CD, as defined by Harvey-Bradshaw score ≥ 4 and one objective sign of inflammation (CRP 5mg/L and/or fecal calprotectin 250 µg/g and/or radiologic and/or endoscopic evidence of disease activity) who
Like
Comment
Share
